Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer (NLCCRIT-LARC)
Neoadjuvant Long-course Chemoradiotherapy Followed by PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Zhanlong Shen, M.D.
- Phone Number: +86 13810230190
- Email: shenzhanlong@pkuph.edu.cn
Study Contact Backup
- Name: Shidong Zhao, M.D.
- Phone Number: +86 19801168617
- Email: zsdong96@163.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100044
- Peking University People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- aged 18~75
- ECOG score 0~2
- biopsy diagnosed rectal adenocarcinoma, distal margin within 10cm to anal verge
- no distant metastasis, staged II/III (T4b excluded) by MRI
- maximum diameter of rectal cancer lesion≥10mm according to baseline CT or MR
- willing and able to comply with study protocol
- consent to the use of blood and tissue specimens for study
- no history of previous anti-tumor treatment (e.g. radiation, chemo, immuno, bio, herbal, etc.)
- no disorders/diseases of immune system (e.g. systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, pemphigus, dermatomyositis, mixed connective tissue disease, autoimmune hemolytic anemia, hyperthyroidism/hypothyroidism, ulcerative colitis, autoimmune hemolytic anemia, HIV infection, etc.)
- no significant dysfunction of major viscera (e.g. heart, lung, liver, kidney, etc.)
- no jaundice or gastrointestinal obstruction
- no acute/ongoing infection
- no significant irregularities in blood routine test and biochemical test results, particular requirements include: neutrophils≥1.5×109/L, HGB≥80g/L, platelet≥100×109/L, serum creatinine≤1.5×ULN, total bilirubin≤1.5×ULN, ALT、AST≤2.5×ULN
- no social or mental disorder
- for women of child-bearing age, a negative result of serological pregnancy test is required, and effective contraception measures from inclusion till 60 days after the last dose of study drug is required
Exclusion Criteria:
- multiple cancers, or with concomitant malignant tumors besides rectal cancer
- having received any anti-cancer treatment (surgery, drugs, etc.) in the past 5 years
- history of recent major surgery
- with condition that affects the absorption of capecitabine via gastrointestinal tract (e.g. inability to swallow, nausea, vomiting, chronic diarrhea, etc.)
- with uncontrolled, severe, concomitant diseases of any sort
- allergic to any of the ingredients under study
- estimated survival ≤ 5 years due to any reason
- preparing for or having previously received organ or bone marrow transplant
- having received immunosuppressive or systemic hormone therapy for immunosuppressive purposes within 1 month prior to inclusion
- for patients with history of disorder of central nervous system, investigator discretion is required as to whether the clinical severity prevents the signing of informed consent or affects the patient or oral medication compliance
- with other conditions/issues that may affect the study results or cause the study treatment to be terminated halfway (e.g. alcoholism, drug abuse, etc.)
- pregnant or lactating women, or women intending on conception during treatment period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: nCRT+PD-1
Long-course chemoradiation followed by PD-1 inhibition (Sintilimab 200mg, 3 times, 2-week interval) starting on Day 15 after completion of radiation therapy.
TME surgery is scheduled in 6 weeks after completion of radiation.
|
45 Gy radiation dose in 25 fractions to the pelvis
200mg Sintilimab after radiation (3 times, 2-week interval)
Other Names:
TME surgery for 6~8 weeks after radiation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
pCR rate
Time Frame: within 1 week after surgery
|
pathological complete response rate
|
within 1 week after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
sphincter preserving rate
Time Frame: instantly after surgery
|
proportion of patients with preserved anal sphincter
|
instantly after surgery
|
|
immune-related adverse event rate
Time Frame: from commencing of PD-1 inhibition to the 30th day after surgery
|
adverse event rate that is deemed to be associated with PD-1 inhibition
|
from commencing of PD-1 inhibition to the 30th day after surgery
|
|
treatment-related adverse event rate
Time Frame: from commencing of treatment to the 30th day after surgery
|
adverse event rate that is deemed to be associated with all treatments
|
from commencing of treatment to the 30th day after surgery
|
|
incidence rate of surgical complications
Time Frame: within 30 days after surgery
|
incidence rate of surgical complications within 30 days after surgery
|
within 30 days after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Zhanlong Zhanlong, M.D., Peking University People's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2023PHB222
- Z220014 (Other Grant/Funding Number: Beijing Municipal Natural Science Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.